Kinoxis is advancing KNX100; a small molecule drug candidate with a highly differentiated mechanism of action that has demonstrated efficacy across multiple animal models and has been proven to be safe and well-tolerated in humans. KNX100 has the potential to be a first-in-class transdiagnostic treatment option for many patients suffering from agitation & aggression as well as substance use disorders.
Kinoxis’ second program is developing compounds that target the oxytocin receptor through partial agonism. This work is conducted under a strategic partnership and licensing agreement with Boehringer Ingelheim.
© Kinoxis Therapeutics | All Rights Reserved | Website by Graphink Design and Integrale Marketing